Genetic Test Evaluation

understanding how genetic tests impact patient management

Guardant360 (Guardant Health Inc.)

December 11, 2018

Guardant360 is a liquid biopsy noninvasive blood screen used to identify actionable alterations across all solid tumor sites and provide a report, which identifies Food and Drug Administration (FDA)-approved treatments and clinical trials to help guide treatment decisions. The focus of this review is to assess the evidence that supports the use of Guardant360 as a decision-making tool, which identifies potentially actionable genetic mutations to help guide treatment options.